Web Exclusives
Web Exclusives | October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Whole-Body MRI Found Superior to Bone Scan for Prognosis in Patients with Metastatic Prostate Cancer
Web Exclusives | October 19, 2021
Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.
Web Exclusives | September 29, 2021
The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.
Web Exclusives | September 29, 2021
Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.
Web Exclusives | September 29, 2021
Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.
Web Exclusives | September 29, 2021
Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.
Web Exclusives | September 29, 2021
Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.
Web Exclusives | September 17, 2021
In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups.
Web Exclusives | September 17, 2021
Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment.
Web Exclusives | September 17, 2021
Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment.
Web Exclusives | September 17, 2021
Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations.
Web Exclusives | August 23, 2021
Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.
Web Exclusives | August 23, 2021
Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.
Web Exclusives | August 23, 2021
A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.
Web Exclusives | August 23, 2021
A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC.
Web Exclusives | July 28, 2021
Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.
Web Exclusives | July 28, 2021
A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.
Web Exclusives | July 28, 2021
Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRASG12C-mutated NSCLC subtypes.
Web Exclusives | July 28, 2021
Results from an incidental lung nodule program implemented in a community healthcare system demonstrates this program detects lung cancer in patients who are otherwise ineligible for LDCT screening.
Web Exclusives | June 23, 2021
Patients with advanced KRASG12C harboring NSCLC maintained quality of life and physical functioning with tolerable side effects while being treated with sotorasib.
Web Exclusives | June 23, 2021
Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.
Web Exclusives | June 23, 2021
A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.
Web Exclusives | June 23, 2021
Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.
Web Exclusives | June 23, 2021
Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRASG12C-mutated NSCLC.
Web Exclusives | May 27, 2021
The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.
Web Exclusives | May 27, 2021
Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
Web Exclusives | May 27, 2021
Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.
Web Exclusives | May 27, 2021
An investigational treatment for second-line treatment of NSCLC was found to be well tolerated and active against KRAS mutations, according to the results of a new study.
Web Exclusives | April 2, 2021
To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.
Web Exclusives | April 2, 2021
Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512